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Smoldering myeloma (SMM) is a pre-malignant monoclonal gammopathy with about 10% annual 
risk to progress to active multiple myeloma (MM).1 The International Myeloma Working Group 
(IMWG) has recently updated SMM diagnostic criteria.2 The previously defined “ultra high-risk” 
SMM (characterized by specific biomarkers associated with upper than 80% risk of progression to 
symptomatic MM within 2 years) has been included among patients with active MM. SMM is 
biologically heterogeneous and encompasses patients with a very low rate of progression to 
symptomatic MM, similar to what occurs in patients with monoclonal gammopathy of uncertain 
significance (MGUS), as well as patients who acquired organ damage and progress to active MM 
within five years from diagnosis.3  
The molecular mechanisms involved in the SMM-to-MM progression are still far to be fully 
understood. Genomic studies indicate that the genetic aberrations that characterize MM patients 
are already present in SMM ones,1,4 who present similar mutational and copy number alteration 
load.5 Moreover, a 4-gene score integrated with clinical features has been identified as a putative 
predictor of high-risk SMM.6 However, few data are available on the transcriptional profiles of SMM 
patients in relationship to the progression to active MM,7-9 overall indicating minimal differential 
expression either in coding or non-coding RNA fraction. To date, data are still lacking which 
describe the transcriptional profiles of plasma cells (PCs) from paired samples obtained at the time 
of SMM and at MM onset.  
Herein, for the first time we compared the transcriptome of purified bone marrow (BM) CD138+ 
PCs from paired samples of SMM patients progressed to active MM (P-SMM), aimed at describing 
any possible common transcriptional discrepancy that may help to understand the intra-patient 
disease evolution; at the same time, we investigated the transcriptional differences between P-
SMM and a subset of non-progressed SMM (NP-SMM) for a median follow up of more than three 
times the time to progression of P-SMM. 
To this aim a total number of 21 SMM patients (Table 1a-b), admitted to the Hematological Unit of 
the Parma Hospital over the last 11 years, were considered: 11 NP-SMM and 10 P-SMM for whom 
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paired active MM samples were available. SMM patients were diagnosed according to the 
International Myeloma Working Group (IMWG) revised criteria2 and stratified by known risk factors 
of progression3 as previously described.10 All the patients enrolled in this study were anti-MM 
therapy naïve. The study was approved by the local Ethics Committee and written informed 
consent was obtained from all the patients involved in the study. Median age at diagnosis was 71 
years (range 43-84) in P-SMM and 74 years (range 38-86) in NP-SMM. The median percentage of 
bone marrow plasma cells (BMPCs) at diagnosis in the 10 P-SMM was 27,5% (range 13-40%). 
One of 10  patient had monoclonal M component ≥ 3 g/dL, whereas 80% of patients presented with 
immunoparesis and high-risk cytogenetic features - either del(17p), or t(4;14) - were detected in 3 
of 9 cases. The median time to progression was 15,5 months and all patients progressed with 
onset of CRAB features. The 11 NP-SMM patients had 12% median percentage of BMPCs (range 
10-25%) and 82% of them presented with immunoparesis; high-risk cytogenetic features were 
detected in 5 of the 9 patients with enough BMPCs to allow examination. According to Mayo 
score3, available in 8 NP-SMM, half patients were classified as intermediate-risk and the other half 
were low-risk. Median follow up in NP-SMM was 56 months. Primary CD138+ PCs were purified by 
immunomagnetic method using anti-CD138 mAb-coated microbeads (MACS, Miltenyi Biotec, 
Bergisch-Gladbach, Germany) from BM aspirate. Total RNA was extracted using RNeasy kit 
(Qiagen, Hilden, Germany) and global expression profiles of 19012 protein-coding and 13972 long 
non-coding RNAs (lncRNAs) were extracted from GeneChip® ClariomD arrays (Affymetrix, Thermo 
Fisher Scientific, USA) analyzed using RMA normalization procedure9 and annotations based on 
Gencode project (version 26) provided by the University of Michigan 
(http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF/22.0.0/genecodeg.asp). 
Data are publicly available on NCBI GEO repository under accession GSE117847. Rank Product9 
and Gene Set Enrichment Analysis (GSEA) were used for differential and functional analyses. 
GSEA analyses on the global gene expression profiles of P-SMM compared to NP-SMM cases 
revealed a down-regulation of antigen processing gene set (Supplementary Figure 1A), whereas 
genes specifically associated with MM proliferation and hyperdiploidy were positively modulated in 
P-SMM cases (Supplementary Figure 1B). Interestingly, this observation was consistent with 
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previously published data showing that, among the gene expression-based molecular subtypes,11 
the proliferation (PR) subtype significantly correlates with progression in asymptomatic myeloma 
patients.12 Additionally, we found 273 genes significantly modulated in P-SMM compared to NP-
SMM (Supplementary Table 1). Specifically, among the 30 genes with at least a 2-fold change in 
expression levels, the Wnt inhibitors FRZB and DKK1, the adhesion molecule CDH2 and the pro-
angiogenic CTGF were up-regulated in association with progression to MM (Figure 1A). 
Subsequently, we confirmed the significant up-regulation of DKK1 (Hs00183740_m1), FRZB 
(Hs00173503_m1), CDH2 (Hs00983056_m1) and CTGF (Hs00170014_m1) mRNA in BM CD138+ 
cells of P-SMM compared to NP-SMM by quantitative real-time PCR (TaqMan Assay, Life 
Technology, USA) performed on Light Cycler 480 (Roche Diagnostics, Italy) following a standard 
protocol. In these experiments, GAPDH (Hs99999905_m1) was used as housekeeping gene and 
2-ΔΔCt method was applied to calculate the mRNA fold change variation (Supplementary Figure 2). 
Moreover, ELISA assays for FRZB protein (Abbexa, UK), namely Secreted Frizzled Related 
Protein (sFRP)-3, were performed on frozen BM plasma of the same patients’ cohort, where 
available, and indicated that median sFRP-3 levels in NP-SMM patient was significantly lower than 
in P-SMM group, as well (p=0.032, Supplementary Figure 3). Accordingly, we have recently 
demonstrated that BM DKK-1 protein levels were significantly higher in SMM patients who 
progress to active MM, in comparison with those non-progressed.10 Additionally, specific 
expression pattern of 65 lncRNAs (7 higher than 2 fold-change) was observed in the comparison 
between P- and NP-SMM cases (Supplementary Table 2), as also recently reported.9 Among the 
most differentially expressed lncRNAs, the most part of them have still an unknown function in the 
MM cell biology and pathophysiology, and still few evidences have been provided in literature. 
Modulation of the lncRNA AC092611.2 (antisense to the proximal GATB gene) has been described 
in juvenile myelomonocytic leukemia,13 whereas AL138899.1 was reported as downregulated in T-
cells acute lymphoblastic leukemia tumors compared with immature thymocytes14. Major evidences 




Conversely, the major finding of our analysis was that very similar expression profiles were 
observed between the 10 paired SMM - MM samples. In fact, no significant differentially expressed 
coding genes and lncRNAs were observed in the comparison between paired cases, thus 
suggesting that the progression of SMM to active MM was not associated to significant 
modification of the transcriptional profiles of PCs. A general portrait was offered by Principal 
Component Analysis of the most variable protein-coding genes and lncRNAs throughout the entire 
dataset, which evidenced that NP-SMM agglomerated in a somehow distinguishable cloud from P-
SMM patients, who conversely tended to aggregate according to patient’s source (Figure 1B). Of 
note, in the paired P-SMM and MM samples any further deregulation was not observed in the gene 
expression levels of the previously described 30 genes, including the Wnt inhibitors FRZB and 
DKK1 differentially expressed between P-SMM and NP-SMM.  
Overall, our findings on the up-regulation of Wnt inhibitors, such as DKK1 and FRZB by CD138+ 
MM cells, in P-SMM patients sustains the hypothesis that high levels of these molecules produced 
by MM cells16 and also BM mesenchymal stromal cells17, 18 may influence the microenvironment, 
exerting a possible immunosuppressive effect19 that leads to the progression of SMM towards 
active MM. Moreover, our data in a cohort of SMM with a short time to progression indicates that 
the transcriptome of the PCs of SMM patients who progressed to MM did not significantly change 
throughout the progression. Albeit a larger study cohort and longer follow up would be undoubtedly 
desirable for confirmation, our data strongly suggested that the transcriptional alterations of PCs 
observed in MM patients are indeed already present at the stage of smoldering disease. This 
prompts to support the notion that the alterations in the microenvironment cells could be critical in 
the progression from SMM to active MM.3  
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AGE at diagnosis (yrs)           
Median (range) 74 (38-86) 71 (43-84) 72 (46-86) 0,77 0,79 
SEX           
Male 9 (81,8%) 4 (40%) 4 (40%)     
Female 2 (18,2%) 6 (60%) 6 (60%)     
ISOTYPE           
k 7 (63,6%) 9 (90%) 9 (90%)     
l 4 (36,4%) 1 (10%) 1 (10%)     
HEAVY CHAIN           
IgG 9 (81,8%) 8 (80%) 8 (80%)     
IgM 2 (18,2%) 2 (20%) 2 (20%)     
ISS           
I / / 4 (40%)     
II / / 4 (40%)     
III / / 2 (20%)     
R-ISS           
I / / 1 (10%)     
II / / 6 (60%)     
III / / 1 (10%)     
N.D. / / 2 (20%)     
CRAB           
Yes / / 10 (100%)     
No / / 0     
slim CRAB           
Yes 0 0 /     
No 11 (100%) 10 (100%) /     
IMMUNOPARESIS           
Yes 9 (81,8%) 8 (80%) 10 (100%)     
No 2 (18,2%) 2 (20%) 0     
BMPCs %           
Median (range) 12 (10-25) 27,5 (13-40) 35 (20-80) 0,054167 0,00102 
MONOCLONAL COMPONENT (g/dL)           
Median (range) 1,6 (0,5-2,9) 2,45 (1-4,5) 3,4 (1,4-7,4) 0,064973 0,37854 
CYTOGENETICS           
High Risk 5 (45,4%) 3 (30%) 4 (40%)     
Low Risk 4 (36,4%) 6 (60%) 5 (50%)     
N.D. 2 (18,2%) 1 (10%) 1 (10%)     
FOLLOW UP (months)           
Median (range) 56 (9-132)   /     
TTP (months)           
Median (range) / 15,5 (5-44) /     
Abbreviations: yrs, years; BMPCs, bone marrow plasma cells; ISS; International staging system; 
R-ISS, revised international staging system, N.D, not determined; TTP, time to progression. 
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Table 1b: Individual clinical characteristics of the patients enrolled in the study. 
  Sex Age (yrs) Isotype 
Heavy 







FISH   
(Y/N) 
















P-SMM1 F 84 k IgG 25 2.6 Y Y N Y 8 Y N Y Y 
P-SMM2 M 69 k IgG 30 1.4 Y N N Y 16 Y N N N 
P-SMM3 F 79 k IgG 35 2.9 Y N Y Y 5 N N Y N 
P-SMM4 M 83 k IgG 30 2.1 N N Y Y 42 N N Y N 
P-SMM5 F 69 k IgG 30 2.9 Y N N Y 13 Y N Y N 
P-SMM6 M 73 l IgG 20 4.5 Y N Y Y 16 Y N N Y 
P-SMM7 F 43 k IgA 20  1.0 Y 
 
 Y 44 N N Y N 
P-SMM8 M 58 k IgG 13 1.5 N N Y Y 34 Y N Y N 
P-SMM9 F 60 k IgG 25 2.3 Y Y Y Y 15 Y N Y N 
P-SMM10 F 74 k IgA 40 2.6 Y Y N Y 12 Y N N N 
NP-SMM11 M 76 k IgG 20 2.5 Y Y Y N 77 
    
NP-SMM12 M 38 k IgG 12 2.9 Y N Y N 65 
    
NP-SMM13 M 86 k IgG 10 2.7 Y Y N N 132 
    
NP-SMM14 M 58 k IgG 25 2.5 Y Y N N 54 
    
NP-SMM15 M 74 l IgG 15 2.3 Y 
 
 N 61 
    
NP-SMM16 M 76 l IgA 20 1.6 Y N Y N 56 
    
NP-SMM17 M 72 l IgG 12 0.6 N 
 
 N 56 
    
NP-SMM18 M 76 k IgG 16 2.8 Y Y N N 9* 
    
NP-SMM19 F 76 l IgA 12 0.5 Y N N N 90 
    
NP-SMM20 M 73 k IgG 12 2.6 Y Y N N 42 
    
NP-SMM21 F 38 k IgG 11 1.2 N N  N 49 
    
Abbreviations: yrs, years; BMPCs, bone marrow plasma cells; FISH, fluorescence in situ hybridization; HY: hyperdiploid; MC, monoclonal component; 
Y, yes; N, no. 




Figure 1. Differential transcriptomic profile between not progressed and progressed 
smoldering and paired myeloma samples. A) Heatmap of the 30 most variable coding genes 
(highlighted in light blue in Supplementary Table 1) with at least 2-fold change in expression levels 
in 10 P-SMM samples versus 11 NP-SMM samples (Prog: progression; NP: not progressed SMM; 
P: progressed SMM); B) 3D visualization of Principal Component (PC) Analysis on the most 
variable transcripts across the whole dataset. NP-SMM (red dots) agglomerated distinguishable 
cloud from P-SMM patients (blue dots), who conversely tended to aggregate with their MM (green 
dots) paired sample. The P-SMM and MM from the same patient’ origin shares the same number 




Supplementary Table 1: 273 differentially expressed genes between NP-SMM and P-SMM 
CD138+ samples. In the table, the 30 most variable genes with a least 2 absolute fold change 
expression variation are highlighted in light blue (pfp: percentage of false prediction using RankProd 
package for Bioconductor). 
Gene symbol- ENSG Fold Change 
(SMM-P vs 
SMM-NP) 
Pfp (<1%) Approximate 
P.value 
FRZB ENSG00000162998 3,080714726 <1x104 <1x104 
LAMP5 ENSG00000125869 3,056234719 <1x104 <1x104 
CNTN5 ENSG00000149972 2,790178571 <1x104 <1x104 
SULF2 ENSG00000196562 2,683843264 <1x104 <1x104 
ITGA8 ENSG00000077943 2,610966057 <1x104 <1x104 
KIT ENSG00000157404 2,569373073 <1x104 <1x104 
CTGF ENSG00000118523 2,44977952 <1x104 <1x104 
DKK1 ENSG00000107984 2,447381302 <1x104 <1x104 
ATP10B ENSG00000118322 2,411963338 <1x104 <1x104 
IL5RA ENSG00000091181 2,283105023 <1x104 <1x104 
FIGN ENSG00000182263 2,239641657 2,00E-04 <1x104 
ABCG2 ENSG00000118777 2,220741728 <1x104 <1x104 
CDH2 ENSG00000170558 2,212389381 <1x104 <1x104 
MFAP3L ENSG00000198948 2,071680133 2,00E-04 <1x104 
TBCEL ENSG00000154114 1,992428771 2,00E-04 <1x104 
BTBD3 ENSG00000132640 1,977066034 2,00E-04 <1x104 
CADM1 ENSG00000182985 1,940993789 1,00E-04 <1x104 
NEB ENSG00000183091 1,939111887 2,00E-04 <1x104 
KIAA1217 ENSG00000120549 1,913509376 3,00E-04 <1x104 
MORC1 ENSG00000114487 1,904761905 2,00E-04 <1x104 
ADGRB3 ENSG00000135298 1,887504719 2,00E-04 <1x104 
TMPRSS11E ENSG00000087128 1,879699248 0,0081 <1x104 
USH2A ENSG00000042781 1,865671642 0,0044 <1x104 
LSAMP ENSG00000185565 1,848770568 2,00E-04 <1x104 
SAMD9L ENSG00000177409 1,807664497 2,00E-04 <1x104 
ELOVL7 ENSG00000164181 1,795009873 6,00E-04 <1x104 
STK17A ENSG00000164543 1,766472355 5,00E-04 <1x104 
RSAD2 ENSG00000134321 1,759943682 2,00E-04 <1x104 
RASSF6 ENSG00000169435 1,759633996 3,00E-04 <1x104 
PDE3A ENSG00000172572 1,749475157 0,006 <1x104 
HGF ENSG00000019991 1,743679163 5,00E-04 <1x104 
DCLK1 ENSG00000133083 1,737619461 0,0012 <1x104 
IFI6 ENSG00000126709 1,735809755 2,00E-04 <1x104 
MAGEC1 ENSG00000155495 1,730702665 2,00E-04 <1x104 
AC024940.1 ENSG00000177359 1,726221302 0,0014 <1x104 
QPCT ENSG00000115828 1,715265866 2,00E-04 <1x104 
ISLR ENSG00000129009 1,677008217 0,0024 <1x104 
HERC5 ENSG00000138646 1,671681712 7,00E-04 <1x104 
LGR4 ENSG00000205213 1,642305797 0,002 <1x104 
CHSY3 ENSG00000198108 1,623903865 0,0012 <1x104 
GPRIN3 ENSG00000185477 1,623376623 4,00E-04 <1x104 
SMAD1 ENSG00000170365 1,619433198 0,0043 <1x104 
IFI44 ENSG00000137965 1,605651895 0,006 <1x104 
PCDHB14 ENSG00000120327 1,601281025 0,0045 <1x104 
MX1 ENSG00000157601 1,595659805 0,0029 <1x104 
TNFSF10 ENSG00000121858 1,593879503 0,0022 <1x104 
TOX ENSG00000198846 1,589319771 0,0028 <1x104 
PDCD4 ENSG00000150593 1,587805653 0,0012 <1x104 
BTAF1 ENSG00000095564 1,587301587 0,0051 <1x104 
SAMD9 ENSG00000205413 1,583782072 0,0024 <1x104 
GRIA3 ENSG00000125675 1,580527896 0,0046 <1x104 
UBE2Q2 ENSG00000140367 1,580028441 0,0027 <1x104 
GOLGA8S ENSG00000261739 1,573316551 0,0014 <1x104 
FGD6 ENSG00000180263 1,569119724 0,0045 <1x104 
RNF168 ENSG00000163961 1,568135487 0,0029 <1x104 
PARP14 ENSG00000173193 1,562988434 0,006 <1x104 
GBP1 ENSG00000117228 1,557147306 0,0053 <1x104 
LTBP1 ENSG00000049323 1,552553951 0,0019 <1x104 
FAM13A ENSG00000138640 1,546072975 0,0038 <1x104 
TECTA ENSG00000109927 1,545117429 0,0064 <1x104 
IFI27 ENSG00000165949 1,542971764 0,0052 <1x104 
HERC6 ENSG00000138642 1,538224888 0,0052 <1x104 
PEAK1 ENSG00000173517 1,536334306 0,0064 <1x104 
NPY4R2 ENSG00000264717 1,535626536 0,0063 <1x104 
IFIT5 ENSG00000152778 1,531862745 0,0063 <1x104 
RNF144B ENSG00000137393 1,530456076 0,0025 <1x104 
EPSTI1 ENSG00000133106 1,522533496 0,0044 <1x104 
FUT8 ENSG00000033170 1,520218912 0,0063 <1x104 
ETV1 ENSG00000006468 1,507386192 0,0025 <1x104 
AP003108.2 ENSG00000256591 1,506931887 0,006 <1x104 
CPED1 ENSG00000106034 1,505570611 0,0056 <1x104 
MTX3 ENSG00000177034 1,503307276 0,0076 <1x104 
PCDHGA9 ENSG00000261934 1,502178158 0,0036 <1x104 
TLR10 ENSG00000174123 1,501050736 0,0048 <1x104 
SLC44A5 ENSG00000137968 1,492760113 0,0045 <1x104 
TRPM7 ENSG00000092439 1,492760113 0,01 <1x104 
CPEB4 ENSG00000113742 1,488759863 0,0052 <1x104 
LRRC70 ENSG00000186105 1,487652484 0,0069 <1x104 
BTLA ENSG00000186265 1,485001485 0,0044 <1x104 
LAP3 ENSG00000002549 1,484340211 0,008 <1x104 
DDX58 ENSG00000107201 1,484340211 0,009 1,00E-04 
JCHAIN ENSG00000132465 1,484119917 0,008 <1x104 
RNPC3 ENSG00000185946 1,476668636 0,01 1,00E-04 
ZNF215 ENSG00000149054 1,466705779 0,0071 <1x104 
STAP1 ENSG00000035720 1,442793248 0,0018 <1x104 
GOLGA8A ENSG00000175265 1,440299582 0,0052 <1x104 
EPHB1 ENSG00000154928 1,424907381 0,0074 <1x104 
BIRC3 ENSG00000023445 1,419849496 0,006 <1x104 
GCNT4 ENSG00000176928 1,408252359 0,0079 <1x104 
EDNRB ENSG00000136160 1,398601399 0,0045 <1x104 
CD200 ENSG00000091972 1,390820584 0,0066 <1x104 
TMEM156 ENSG00000121895 1,387347392 0,0052 <1x104 
KCNS3 ENSG00000170745 1,374381528 0,0073 <1x104 
CTSW ENSG00000172543 1,372118551 5,00E-04 <1x104 
CCR2 ENSG00000121807 1,320829481 0,007 <1x104 
MAML2 ENSG00000184384 1,308557969 0,0063 <1x104 
MT1X ENSG00000187193 1,299545159 0,0067 <1x104 
FAM106A ENSG00000213077 1,251251251 3,00E-04 <1x104 
RGS13 ENSG00000127074 1,246261216 0,0045 <1x104 
AFF2 ENSG00000155966 1,160092807 0,0036 <1x104 
PPBP ENSG00000163736 1,127649977 0,0067 <1x104 
CD44 ENSG00000026508 1,118943717 0,009 1,00E-04 
IFI44L ENSG00000137959 1,98019802 5,00E-04 <1x104 
BVES ENSG00000112276 1,87899286 2,00E-04 <1x104 
TRAT1 ENSG00000163519 1,75070028 0,0012 <1x104 
SCYL2 ENSG00000136021 1,62999185 0,0015 <1x104 
MMP16 ENSG00000156103 1,58755358 0,0078 <1x104 
XAF1 ENSG00000132530 1,57480315 0,0039 <1x104 
ME1 ENSG00000065833 1,52998776 0,0051 <1x104 
MIOS ENSG00000164654 1,52998776 0,0075 <1x104 
FAT4 ENSG00000196159 1,50466446 0,0023 <1x104 
PRKD3 ENSG00000115825 1,50466446 0,0065 <1x104 
STS ENSG00000101846 1,47080453 0,0043 <1x104 
PPARGC1A ENSG00000109819 1,27420999 0,0097 1,00E-04 
EDN1 ENSG00000078401 1,26246686 0,0052 <1x104 
KIAA1324L ENSG00000164659 1,5211439 0,0045 <1x104 
TREML2 ENSG00000112195 -1,88 <1x104 <1x104 
CRISP3 ENSG00000096006 -2,82 <1x104 <1x104 
RASGRP1 ENSG00000172575 -1,258 0,0078 1,00E-04 
YBX3 ENSG00000060138 -1,356 0,0079 1,00E-04 
GAGE12J ENSG00000224659 -1,462 0,0018 <1x104 
ZNF675 ENSG00000197372 -1,477 0,0079 1,00E-04 
ATF3 ENSG00000162772 -1,527 0,0018 <1x104 
CST7 ENSG00000077984 -1,561 0,0033 <1x104 
PGLYRP1 ENSG00000008438 -1,589 0,0034 <1x104 
TGFB2 ENSG00000092969 -1,761 <1x104 <1x104 
HBA1 ENSG00000206172 -1,823 <1x104 <1x104 
FAM106A ENSG00000213077 -0,7992 0,0014 <1x104 
VCAM1 ENSG00000162692 -1,0351 0,0064 <1x104 
TIMD4 ENSG00000145850 -1,2227 0,0025 <1x104 
C1QC ENSG00000159189 -1,2319 0,0093 1,00E-04 
GPRC5D ENSG00000111291 -1,2571 0,0029 <1x104 
RND3 ENSG00000115963 -1,2597 0,0048 <1x104 
PRKG1 ENSG00000185532 -1,2762 0,0033 <1x104 
HIST1H1C ENSG00000187837 -1,2879 0,009 1,00E-04 
SLAMF1 ENSG00000117090 -1,3278 0,0048 <1x104 
AC068896.1 ENSG00000258539 -1,3294 0,005 <1x104 
EDEM3 ENSG00000116406 -1,3403 0,0058 <1x104 
APP ENSG00000142192 -1,3467 0,0034 <1x104 
USP9Y ENSG00000114374 -1,3477 0,0052 <1x104 
NBPF6 ENSG00000186086 -1,3478 0,0018 <1x104 
FAM129A ENSG00000135842 -1,3599 7,00E-04 <1x104 
RHOB ENSG00000143878 -1,3605 0,009 1,00E-04 
CD79A ENSG00000105369 -1,3773 <1x104 <1x104 
OR2T2 ENSG00000196240 -1,3805 0,0091 1,00E-04 
FCRL3 ENSG00000160856 -1,3884 0,0024 <1x104 
CERS6 ENSG00000172292 -1,3906 0,0044 <1x104 
ZNF165 ENSG00000197279 -1,3907 0,0049 <1x104 
OTUD1 ENSG00000165312 -1,3913 0,0033 <1x104 
ATP8B2 ENSG00000143515 -1,4038 0,0091 1,00E-04 
FCER2 ENSG00000104921 -1,4069 0,0063 <1x104 
CCL3 ENSG00000277632 -1,4095 2,00E-04 <1x104 
GRIN2B ENSG00000273079 -1,4114 0,0059 <1x104 
SPATA31D3 ENSG00000186788 -1,4157 0,0033 <1x104 
FOS ENSG00000170345 -1,4199 0,0091 1,00E-04 
CCL18 ENSG00000275385 -1,4226 0,0075 1,00E-04 
LY9 ENSG00000122224 -1,4227 0,0055 <1x104 
GOLPH3L ENSG00000143457 -1,4283 0,0092 1,00E-04 
AIF1 ENSG00000204472 -1,4283 0,0098 1,00E-04 
KCNN3 ENSG00000143603 -1,4311 0,0059 <1x104 
SLAMF6 ENSG00000162739 -1,4508 7,00E-04 <1x104 
NAXE ENSG00000163382 -1,4514 0,0065 <1x104 
GOLGA8H ENSG00000261794 -1,4549 0,0078 1,00E-04 
SEMA4A ENSG00000196189 -1,4562 0,0065 <1x104 
UCHL1 ENSG00000154277 -1,4565 <1x104 <1x104 
JUN ENSG00000177606 -1,4596 0,0091 1,00E-04 
SCN9A ENSG00000169432 -1,4612 8,00E-04 <1x104 
TCEA3 ENSG00000204219 -1,4676 0,0056 <1x104 
NUCB2 ENSG00000070081 -1,4683 0,0077 1,00E-04 
HIST2H2BE ENSG00000184678 -1,4699 0,001 <1x104 
IRF2BP2 ENSG00000168264 -1,4724 0,005 <1x104 
SELL ENSG00000188404 -1,4735 0,0049 <1x104 
PDIA4 ENSG00000155660 -1,4766 0,0033 <1x104 
RNASE6 ENSG00000169413 -1,4768 0,0033 <1x104 
P2RY13 ENSG00000181631 -1,4777 0,0033 <1x104 
DAPK1 ENSG00000196730 -1,4787 0,0025 <1x104 
SLC46A3 ENSG00000139508 -1,4799 0,0063 <1x104 
CA1 ENSG00000133742 -1,4811 0,0048 <1x104 
MEF2D ENSG00000116604 -1,4863 0,0079 1,00E-04 
PLP2 ENSG00000102007 -1,4925 0,0093 1,00E-04 
WARS ENSG00000140105 -1,4951 6,00E-04 <1x104 
FCRL5 ENSG00000143297 -1,4984 0,0062 <1x104 
SGK1 ENSG00000118515 -1,5035 0,0049 <1x104 
GSTA4 ENSG00000170899 -1,5075 0,0065 <1x104 
TYROBP ENSG00000011600 -1,5081 0,0041 <1x104 
HIST1H2AL ENSG00000276903 -1,5094 0,006 <1x104 
HLA-DRA ENSG00000204287 -1,5121 0,0033 <1x104 
NCSTN ENSG00000162736 -1,5156 0,0049 <1x104 
S100A11 ENSG00000163191 -1,5233 0,0073 1,00E-04 
VNN1 ENSG00000112299 -1,5248 0,0059 <1x104 
CDA ENSG00000158825 -1,5289 0,005 <1x104 
HSBP1L1 ENSG00000226742 -1,5296 0,0036 <1x104 
PADI4 ENSG00000159339 -1,5348 0,0079 1,00E-04 
RFLNB ENSG00000183688 -1,5375 0,0011 <1x104 
HOOK1 ENSG00000134709 -1,5377 0,0011 <1x104 
CCND2 ENSG00000118971 -1,5381 <1x104 <1x104 
GAREM1 ENSG00000141441 -1,5389 0,0045 <1x104 
AHSP ENSG00000169877 -1,5438 0,0036 <1x104 
CCND1 ENSG00000110092 -1,5448 0,0013 <1x104 
CD52 ENSG00000169442 -1,5456 0,0028 <1x104 
FCER1G ENSG00000158869 -1,5466 0,0011 <1x104 
ALDH1L2 ENSG00000136010 -1,5591 0,0024 <1x104 
AC136428.1 ENSG00000259680 -1,5608 <1x104 <1x104 
HLA-DMA ENSG00000204257 -1,5635 0,0039 <1x104 
PTGS2 ENSG00000073756 -1,5654 5,00E-04 <1x104 
FCAR ENSG00000186431 -1,5684 0,0035 <1x104 
BPI ENSG00000101425 -1,5805 0,0025 <1x104 
ALAS2 ENSG00000158578 -1,5815 0,0017 <1x104 
ELANE ENSG00000197561 -1,5844 0,0011 <1x104 
ANXA1 ENSG00000135046 -1,5848 7,00E-04 <1x104 
ADA2 ENSG00000093072 -1,5853 0,0013 <1x104 
IGF1R ENSG00000140443 -1,5889 0,0018 <1x104 
SLC7A5 ENSG00000103257 -1,5946 0,0012 <1x104 
OR51A4 ENSG00000205497 -1,5968 0,0021 <1x104 
ALOX5AP ENSG00000132965 -1,6004 0,0019 <1x104 
ZFY ENSG00000067646 -1,6025 2,00E-04 <1x104 
ERAP2 ENSG00000164308 -1,6109 <1x104 <1x104 
AGA ENSG00000038002 -1,6127 0,0018 <1x104 
TCN1 ENSG00000134827 -1,6213 0,0033 <1x104 
SGPP2 ENSG00000163082 -1,6238 0,0038 <1x104 
HIST2H2BF ENSG00000203814 -1,6316 5,00E-04 <1x104 
LCN2 ENSG00000148346 -1,6355 0,0011 <1x104 
PLAGL1 ENSG00000118495 -1,6373 0,0018 <1x104 
MS4A3 ENSG00000149516 -1,6445 8,00E-04 <1x104 
ZNF608 ENSG00000168916 -1,6507 0,0011 <1x104 
PTP4A3 ENSG00000184489 -1,6546 <1x104 <1x104 
IL6R ENSG00000160712 -1,6551 2,00E-04 <1x104 
CYBB ENSG00000165168 -1,6687 <1x104 <1x104 
HBA2 ENSG00000188536 -1,6713 4,00E-04 <1x104 
RNASE3 ENSG00000169397 -1,6762 7,00E-04 <1x104 
C1orf21 ENSG00000116667 -1,6764 <1x104 <1x104 
TIMP1 ENSG00000102265 -1,6807 <1x104 <1x104 
SERPINB10 ENSG00000242550 -1,6976 5,00E-04 <1x104 
MPO ENSG00000005381 -1,7059 1,00E-04 <1x104 
RNASE2 ENSG00000169385 -1,7062 2,00E-04 <1x104 
MAL ENSG00000172005 -1,7142 <1x104 <1x104 
DUSP10 ENSG00000143507 -1,7194 <1x104 <1x104 
AC008770.2 ENSG00000257355 -1,7321 <1x104 <1x104 
CTSG ENSG00000100448 -1,7513 <1x104 <1x104 
MYADM ENSG00000179820 -1,7529 <1x104 <1x104 
CST3 ENSG00000101439 -1,7774 <1x104 <1x104 
EIF1AY ENSG00000198692 -1,7776 <1x104 <1x104 
MMP9 ENSG00000100985 -1,7797 5,00E-04 <1x104 
LYZ ENSG00000090382 -1,7816 <1x104 <1x104 
ANXA3 ENSG00000138772 -1,7838 1,00E-04 <1x104 
RASD1 ENSG00000108551 -1,8009 <1x104 <1x104 
HBB ENSG00000244734 -1,8046 <1x104 <1x104 
PLTP ENSG00000100979 -1,8055 <1x104 <1x104 
PARP15 ENSG00000173200 -1,8187 <1x104 <1x104 
C16orf54 ENSG00000185905 -1,8306 <1x104 <1x104 
DOCK11 ENSG00000147251 -1,8377 <1x104 <1x104 
ORM1 ENSG00000229314 -1,8525 <1x104 <1x104 
CAMP ENSG00000164047 -1,8581 <1x104 <1x104 
S100A8 ENSG00000143546 -1,8736 <1x104 <1x104 
MNDA ENSG00000163563 -1,8818 <1x104 <1x104 
PLBD1 ENSG00000121316 -1,8968 <1x104 <1x104 
SPN ENSG00000197471 -1,9212 <1x104 <1x104 
KDM5D ENSG00000012817 -1,9594 <1x104 <1x104 
TSPAN6 ENSG00000000003 -2,0533 <1x104 <1x104 
P2RX1 ENSG00000108405 -2,0849 <1x104 <1x104 
UTY ENSG00000183878 -2,0884 <1x104 <1x104 
OLFM4 ENSG00000102837 -2,1122 <1x104 <1x104 
CEACAM8 ENSG00000124469 -2,1799 <1x104 <1x104 
VPREB3 ENSG00000128218 -2,2277 <1x104 <1x104 
ZNF681 ENSG00000196172 -2,2424 <1x104 <1x104 
DEFA4 ENSG00000164821 -2,3089 <1x104 <1x104 
S100A9 ENSG00000163220 -2,3698 <1x104 <1x104 
CD27 ENSG00000139193 -2,3818 <1x104 <1x104 
LTF ENSG00000012223 -2,3818 <1x104 <1x104 
DDX3Y ENSG00000067048 -2,4111 <1x104 <1x104 
S100A12 ENSG00000163221 -2,5974 <1x104 <1x104 
CDR1 ENSG00000184258 -2,6349 <1x104 <1x104 
MMP8 ENSG00000118113 -2,6568 <1x104 <1x104 
CRISP3 ENSG00000096006 -2,82 <1x104 <1x104 
 
 
Supplementary Table 2: 65 long non-coding genes differentially expressed in P-SMM versus NP-
SMM CD138+ samples. In the table, the 7 most variable genes with a least 2 absolute fold change 
expression variation are highlighted in light blue. 








AC012414.5 ENSG00000260409 2,822466836 <1x104 <1x104 
XIST ENSG00000229807 2,811357886 <1x104 <1x104 
AC092611.2 ENSG00000251603 2,225189141 <1x104 <1x104 
AL138899.1 ENSG00000176320 2,138122728 <1x104 <1x104 
AL390208.1 ENSG00000271730 2,133105802 <1x104 <1x104 
AL391834.1 ENSG00000272842 2,030869212 <1x104 <1x104 
DUXAP8 ENSG00000206195 1,944390434 <1x104 <1x104 
LINC02024 ENSG00000241213 1,94024059 0,001 <1x104 
NPTN-IT1 ENSG00000281183 1,911680367 <1x104 <1x104 
LINC01480 ENSG00000270164 1,908396947 <1x104 <1x104 
AF127936.2 ENSG00000232884 1,897173212 <1x104 <1x104 
NAV2-IT1 ENSG00000255270 1,706484642 0,001 <1x104 
AP000756.1 ENSG00000255183 1,693766938 0,0077 <1x104 
AC006058.1 ENSG00000261786 1,691474966 6,00E-04 <1x104 
AC124290.1 ENSG00000253524 1,66002656 0,0035 <1x104 
AC092691.1 ENSG00000239268 1,653165813 0,0079 <1x104 
RSF1-IT2 ENSG00000254985 1,638269987 0,0042 <1x104 
AC007326.5 ENSG00000284294 1,636929121 0,0029 <1x104 
AL158206.1 ENSG00000260912 1,634788295 0,0039 <1x104 
DISC1FP1 ENSG00000261645 1,623903865 0,0081 <1x104 
AC012485.3 ENSG00000283635 1,570105197 0,0062 <1x104 
FAM74A1 ENSG00000215112 1,550147264 0,0027 <1x104 
AC090970.1 ENSG00000259398 1,541307028 0,0087 <1x104 
LARGE-IT1 ENSG00000232081 1,531159087 0,0089 <1x104 
AC010931.2 ENSG00000248540 1,521606817 0,0097 <1x104 
AL139351.1 ENSG00000276923 1,500150015 0,0058 <1x104 
AC020978.8 ENSG00000263276 1,449485433 0,0104 <1x104 
PWAR6 ENSG00000257151 1,444251878 0,0082 <1x104 
LINC01484 ENSG00000253686 1,43000143 0,0106 <1x104 
AC007684.1 ENSG00000273035 1,357404642 0,0099 <1x104 
AC025031.3 ENSG00000274591 1,35501355 0,0087 <1x104 
AL353753.1 ENSG00000276759 1,3374348 0,0093 <1x104 
AC106882.1 ENSG00000248571 1,323977228 0,0096 <1x104 
AC099793.1 ENSG00000259815 1,313887794 0,0102 <1x104 
AL022067.1 ENSG00000269919 1,254862593 0,0097 <1x104 
AC107983.2 ENSG00000273018 1,156203029 0,0062 <1x104 
LINC01055 ENSG00000235366 1,155134573 0,0104 <1x104 
AL078639.1 ENSG00000281508 -4,1746 <1x104 <1x104 
AC245128.3 ENSG00000268734 -1,8731 <1x104 <1x104 
Z93241.1 ENSG00000270022 -1,8142 <1x104 <1x104 
AC092279.1 ENSG00000268362 -1,7979 5,00E-04 <1x104 
AC136475.8 ENSG00000270105 -1,7237 8,00E-04 <1x104 
LINC00582 ENSG00000229228 -1,6621 0,0021 <1x104 
AC012313.7 ENSG00000269106 -1,6412 0,0012 <1x104 
AC087463.3 ENSG00000261598 -1,5986 7,00E-04 <1x104 
AC103591.3 ENSG00000273338 -1,5945 4,00E-04 <1x104 
AP001330.5 ENSG00000271882 -1,5859 0,0017 <1x104 
AC092120.2 ENSG00000261692 -1,5822 0,002 <1x104 
HYMAI ENSG00000283122 -1,5637 0,0094 <1x104 
AC007032.1 ENSG00000273320 -1,5502 0,0022 <1x104 
AC007556.1 ENSG00000235321 -1,5454 7,00E-04 <1x104 
AC009812.4 ENSG00000260317 -1,4977 0,0016 <1x104 
AC008074.3 ENSG00000260101 -1,4782 0,0022 <1x104 
AC008440.2 ENSG00000232220 -1,4702 0,0013 <1x104 
CYTOR ENSG00000222041 -1,4344 0,0051 <1x104 
AC016831.5 ENSG00000271204 -1,4223 0,01 <1x104 
TTTY15 ENSG00000233864 -1,414 0,0014 <1x104 
AC245041.2 ENSG00000276850 -1,4135 0,0052 <1x104 
AC104248.1 ENSG00000253796 -1,412 0,0021 <1x104 
AC017002.1 ENSG00000224959 -1,3805 0,0018 <1x104 
AL449106.1 ENSG00000273062 -1,3769 0,0076 <1x104 
AC026369.3 ENSG00000256948 -1,3674 6,00E-04 <1x104 
LINC02085 ENSG00000214407 -1,3353 0,0098 <1x104 
AP000240.1 ENSG00000273017 -1,3253 0,0038 <1x104 
AC010889.1 ENSG00000260197 -1,2938 0,0051 <1x104 
 
  
SUPPLEMENTARY FIGURE  
Supplementary Figure 1. Enrichment plots derived from Gene Set Enrichment Analysis (GSEA) in 
P-SMM (group 1) versus NP-SMM (group 0) samples A) Antigen processing and presentation gene 
set enrichment plot in Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database B) 
Enrichment plots of genes sets associated with proliferation and hyperdiploidy in MM according to 




Supplementary Figure 2. The expression of DKK1, FRZB, CTGF and CDH2 mRNA were evaluated 
by Real-time PCR in BM CD138+ cells of the same patients’ cohort of the gene expression analyses. 
Graphs represent median with range of -ΔCt (cycle threshold). Fold change was calculated of P-
SMM patients versus NP-SMM assuming median ΔCt of NP-SMM group as control condition (fold 
change. DKK1=1,58; FRZB=1,61; CTGF=2,14; CDH2=19,56). GAPDH was used as housekeeping 
gene and 2-ΔΔCt method was used to calculate the fold change. (*= fold change >1,5) 
 
  
Supplementary Figure 3. BM plasma samples of the same patient cohort, when available (7 P-
SMM and 10 NP-SMM), were tested by ELISA for FRZB protein. Graphs represent the median value 
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